Menu Close Call 1-800-CEDARS-1 toggle search form Close
COVID-19 (Coronavirus)
VACCINE INFORMATION AND MORE

Andrew E. Hendifar, MD

Medical Director, Pancreatic Cancer

Assistant Professor, Medicine

Andrew E. Hendifar, MD

Samuel Oschin Cancer Center
127 S San Vicente Blvd - 7th Floor
Los Angeles, CA
90048

Phone:

310-423-2217

Fax:

310-967-8486

Andrew E. Hendifar, MD

Medical Director, Pancreatic Cancer

Assistant Professor, Medicine

  • IM/Hematology/Oncology

The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves on the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars Sinai he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program.

View NIH Biographical Sketch

  • Medical School: Tulane University School of Medicine, 2003
  • Internship: Los Angeles County + USC Medical Center, 2006
  • Residency: Los Angeles County + USC Medical Center, 2007
  • Fellowship: University of Southern California, 2010

View CV

English / Spanish

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.